LOGIN  |  REGISTER
Chimerix
Viking Therapeutics

Zynex Announces 1 Millionth Patient Milestone

August 10, 2023 | Last Trade: US$7.86 0.04 0.51

ENGLEWOOD, Colo., Aug. 10, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced that, since its founding, the company has treated more than 1 million patients through its pain management division.

Zynex manufactures and sells the NexWave electrotherapy device, an FDA-cleared, prescription-strength, non-invasive, and non-opioid approach to managing acute and chronic pain. The company's pain management division also distributes and private labels several high-quality devices such as low-back support, cervical traction, bracing, and hot/cold therapy. Zynex is bringing a series of in-patient hospital monitoring devices through FDA clearance in addition to its pain management and therapeutic products.

Thomas Sandgaard, Founder and CEO, commented on the company's milestone, "I'm incredibly proud to have surpassed treating 1 million patients. Reaching such a tremendous landmark for the company is a testament to the tireless efforts and teamwork that each of our employees brings to this company.

"Our journey to this moment has been filled with challenges, growth, and triumphs, and it's awe-inspiring to think about the countless lives we've touched. Success is not measured merely in numbers, but also in the positive change we've effected through proven non-opioid pain relief."

About Zynex, Inc.

Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com.

Investor Relations Contact:
Quinn Callanan, CFA or Brian Prenoveau, CFA
MZ Group – MZ North America
This email address is being protected from spambots. You need JavaScript enabled to view it.
+949 694 9594

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB